Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) - Meet the investigator

 

In this insightful peer-to-peer discussion, Prof Andrew Coats, University of Warwick, UK and President-elect of the Heart Failure Association (HFA), discusses with Prof Stefan Anker, Charité University, Berlin, DE, the significance of EMPA-REG OUTCOME, its broader ramifications for SGLT2 inhibitors, and what the future may hold.